Is breast tumor progression really linear?
Polyak
Kornelia
K
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA. kornelia_polyak@dfci.harvard.edu
D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism; D001940:Breast; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology*; D018270:Carcinoma, Ductal, Breast / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000473:pathology / Q000503:physiopathology*; D018450:Disease Progression; D042822:Genomic Instability; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D014411:Neoplastic Stem Cells / Q000502:physiology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53